In addition, preclinical efficacy experiments demonstrated that CGM097 could induce tumour regressions with daily dosing similar and consistent with other p53/MDM2 inhibitors5,20–22 However, here we report that similar preclinical regressions could be reached with an alternative dosing regimen, especially with the 3qw regimen, which may have the best therapeutic index based on the low weekly dose and Cave-ss compared with the daily treatment regimen, and the low Cmax-ss compared with the 2qw and 3 days on/4 days off regimens. Here, TP53 is linked to neoplasm.